Dr Christopher Corless

Christopher L. Corless, M.D., Ph.D.

Christopher Corless

After undergraduate studies at the Univ. of California, Berkeley, Dr. Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women's Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University as an Assistant Professor. He has served as the residency program director in Pathology and as medical director of surgical pathology for OHSU Hospital, and is now the Chief Medical Officer for the Knight Diagnostic Laboratories at OHSU. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to Professor of Pathology in 2004 and is an author on over 200 publications.

Membership in Professional Organizations (Past and Present)

  •  Am. Association for Cancer Research
  • Am. Society of Clinical Oncology
  • Am. Society of Clinical Pathologists
  • Association for Molecular Pathology
  • Gastrointestinal Pathology Society
  • Pacific Northwest Society of Pathologists
  • Southwest Oncology Group (SWOG)
  • United States & Canadian Academy of Pathology


Co-Inventor: Treatment of seminoma with imatinib mesylate (Gleevec, formerly STI571) – patent pending.

Co-Inventor: U.S. Patent 7,595,154 B2.PDGFRA mutations as targets for diagnosis and treatment.


1.Corless CL and Boime I. Differential secretion of O-glycosylated gonadotropin alpha-subunit and luteinizing hormone (LH) in the presence of LH-releasing hormone. Endocrinology 117: 1699-706, 1985.

2.Corless CL, Bielinska M, Ramabhadran TV, Daniels-McQueen S, Otani T, Reitz BA, Tiemeier DC, and Boime I. Gonadotropin alpha subunit. Differential processing of free and combined forms in human trophoblast and transfected mouse cells. J Biol Chem 262: 14197-203, 1987.

3.Corless CL, Matzuk MM, Ramabhadran TV, Krichevsky A, and Boime I. Gonadotropin beta subunits determine the rate of assembly and the oligosaccharide processing of hormone dimer in transfected cells. J Cell Biol 104: 1173-81, 1987.

4.Matzuk MM, Krieger M, Corless CL, and Boime I. Effects of preventing O-glycosylation on the secretion of human chorionic gonadotropin in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 84: 6354-8, 1987.

5.Rice GE, Munro JM, Corless C, and Bevilacqua MP. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 138: 385-93, 1991.

6.Corless CL, Mendoza A, Collins T, and Lawler J. Colocalization of thrombospondin and syndecan during murine development. Dev Dyn. 193: 346-58, 1992.

7.Munro JM, Lo SK, Corless C, Robertson MJ, Lee NC, Barnhill RL, Weinberg DS, and Bevilacqua MP. Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues. Am J Pathol 141: 1397-408, 1992.

8.Ernst CA, Zhang YJ, Hancock PR, Rutledge BJ, Corless CL, and Rollins BJ. Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains. J Immunol 152: 3541-9, 1994.

9.Silverman SG, Lee BY, Seltzer SE, Bloom DA, Corless CL, and DF. Small (< or = 3 cm) renal masses: correlation of spiral CT features and pathologic findings. AJR Am J Roentgenol 163: 597-605, 1994.

10.Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, and Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140-5, 1995.

11.Renshaw AA and Corless CL. Papillary renal cell carcinoma. Histology and immunohistochemistry. Am J Surg Pathol. 19: 842-9, 1995.

12.Rutledge BJ, Rayburn H, Rosenberg R, North RJ, Gladue RP, Corless CL, and Rollins BJ. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol 155: 4838-43, 1995.

13.Boudousquie AC, Lawce HJ, Sherman R, Olson S, Magenis RE, and Corless CL. Complex translocation [7;22] identified in an epithelioid hemangioendothelioma. Cancer Genet Cytogenet 92: 116-21, 1996.

14.Corless CL, Aburatani H, Fletcher JA, Housman DE, Amin MB, and Weinberg DS. Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol 5: 53-64, 1996.

15.Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, and Bischoff J. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 148: 1181-91, 1996.

16.Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, and Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149: 1553-64, 1996.

17.Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, and Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56: 4159-63, 1996.

18.Saxon RR, Mendel-Hartvig J, Corless CL, Rabkin J, Uchida BT, Nishimine K, and Keller FS. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 7: 487-97, 1996.

19.Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, and Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 21: 621-35, 1997.

20.Corless CL, Kibel AS, Iliopoulos O, and Kaelin WG, Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28: 459-64, 1997.

21.Hapke RJ, Corless C, and Katon RM. Isolated jejunal Crohn's disease in a young woman presenting with malabsorption syndrome and abdominal pain. Am J Gastroenterol 92: 1916-9, 1997.

22.Mannori G, Santoro D, Carter L, Corless C, Nelson RM, and Bevilacqua MP. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol 151: 233-43, 1997.

23.Corless CL, Daut D, Burke R. Localized giant cell vasculitis of the spermatic cord presenting as a mass lesion. J Urologic Pathology 6:235-242, 1997.

24.Nguyen M, Corless CL, Kraling BM, Tran C, Atha T, Bischoff J, and Barsky SH. Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am J Pathol 150: 1307-14, 1997.

25.Pavcnik D, Saxon RR, Kubota Y, Tanihata H, Uchida BT, Corless C, and Keller, FS. Attempted induction of chronic portal venous hypertension with polyvinyl alcohol particles in swine. J Vasc Interv Radiol 8: 123-8, 1997.

26.Renshaw, A. A., Gordon, M., and Corless, C. L. Immunohistochemistry of unclassified sex cord-stromal tumors of the testis with a predominance of spindle cells. Mod Pathol 10: 693-700, 1997.

27.Renshaw AA, Zhang H, Corless CL, Fletcher JA, and Pins MR. Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. Am J Surg Pathol 21: 1203-9, 1997.

28.Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, and Benner, KG. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64: 721-6, 1997.

29.Gordon MD, Corless C, Renshaw AA, and Beckstead J. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol 11: 769-73, 1998.

30.Press RD, Flora K, Gross C, Rabkin JM, and Corless CL. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis. Am J Clin Pathol 109: 577-84, 1998.

31.Rabkin JM, Corless CL, Orloff SL, Benner KG, Flora KD, Rosen HR, and Olyaei A. J. Liver transplantation for disulfiram-induced hepatic failure. Am J Gastroenterol 93: 830-1, 1998.

32.Rabkin JM, Orloff SL, Corless CL, Benner KG, Flora KD, Rosen HR, Keller FS, Barton RE, Lakin PC, Petersen BD, Saxon RR, and Olyaei A. J. Hepatic allograft abscess with hepatic arterial thrombosis. Am J Surg 175: 354-9, 1998.

33.Rabkin JM, Orloff SL, Reed MH, Wheeler LJ, Corless CL, Benner KG, Flora KD, Rosen HR, and Olyaei AJ. Biliary tract complications of side-to-side without T tube versus end-to-end with or without T tube choledochocholedochostomy in liver transplant recipients. Transplantation 65: 193-9, 1998.

34.Rosen HR, Corless CL, Rabkin J, and Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 66: 1627-31, 1998.

35.Giovannucci E, Kantoff P, Spiegelman D, Loughlin KR, Wishnow KI, Corless C, McDermott A, Willet WC, Talcott JA. The epidemic of prostate cancer and the medical literature: a causal association? Prostate Cancer and Prostatic Diseases 1:148-153, 1998

36.Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, and Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation. 65: 1178-82, 1998.

37.Hansen PD, Rogers S, Corless CL, Swanstrom LL, and Siperstien AE. Radiofrequency ablation lesions in a pig liver model. J Surg Res 87: 114-21, 1999.

38.Jarvis MA, Wang CE, Meyers HL, Smith PP, Corless CL, Henderson GJ, Vieira J, Britt WJ, and Nelson JA. Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol 73: 4552-60, 1999.

39.Kelly FJ, Anderson S, Thompson MM, Oyama TT, Kennefick TM, Corless CL, Roman RJ, Kurtzberg L, Pratt BM, and Ledbetter SR. Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol 10: 1264-73, 1999.

40.Lakin PC, Pavcnik D, Bloch RD, Uchida BT, Corless CL, Timmermans HA, and Kubota Y. Percutaneous transjugular kidney biopsy in swine with use of a side-cutting needle with a blunt-tipped stylet. J Vasc Interv Radiol 10: 1229-32, 1999.

41.Orloff SL, Busch AM, Olyaei AJ, Corless CL, Benner KG, Flora KD, Rosen HR, and Rabkin JM. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 177: 418-22, 1999.

42.Orloff SL, Yin Q, Corless CL, Loomis CB, Rabkin JM, and Wagner CR. A rat small bowel transplant model of chronic rejection: histopathologic characteristics. Transplantation 68: 766-79, 1999.

43.Pavcnik D, Uchida BT, Keller FS, Corless CL, and Rosch J. Retrievable IVC square stent filter: experimental study. Cardiovasc Intervent Radiol 22: 239-45, 1999.

44.Rabkin JM, Smith MJ, Orloff SL, Corless CL, Stenzel P, and Olyaei AJ. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 33: 945-7, 1999.

45.Renshaw AA, Granter SR, Fletcher JA, Kozakewich HP, Corless CL, and Perez-Atayde AR. Renal cell carcinomas in children and young adults: increased incidence of papillary architecture and unique subtypes. Am J Surg Pathol 23: 795-802, 1999.

46.Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Rabkin J, Corless CL, and Bouwer HG. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117: 926-32, 1999.

47.Rosen HR, Lentz JJ, Rose SL, Rabkin J, Corless CL, Taylor K, and Chou S. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 68: 1898-902, 1999.

48.Avery AK, Beckstead J, Renshaw AA, and Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 24: 203-10, 2000.

49.Faigel DO, Magaret N, Corless C, Lieberman DA, and Fennerty MB. Evaluation of rapid antibody tests for the diagnosis of Helicobacter pylori infection. Am J Gastroenterol 95: 72-7, 2000.

50.Hahn M, Fennerty MB, Corless CL, Magaret N, Lieberman DA, and Faigel DO. Noninvasive tests as a substitute for histology in the diagnosis of Helicobacter pylori infection. Gastrointest Endosc 52: 20-6. 2000.

51.Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G, Harford WV, Provenzale D, Sontag S, Schnell T, Campbell DR, Durbin TE, Nelson DB, Ewing SL, Triadafilopoulos G, Ramirez FC, Lee JG, Collins JF, Fennerty MB, Johnston TK, Corless CL, McQuaid KR, Sampliner RE, Morales TG, Fass R, Smith R, and Maheshwari Y. Use of Colonoscopy to Screen Asymptomatic Adults for Colorectal Cancer. N Engl J Med 343: 162-168, 2000. [Note: Only first 6 authors listed on Medline]

52.Orloff SL, Yin Q, Corless CL, Orloff MS, Rabkin JM, and Wagner CR. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation 69: 1295-303, 2000.

53.Park JW, Pavcnik D, Uchida BT, Timmermans H, Corless CL, Yamakado K, Yamada K, Keller FS, and Rosch J. Small intestinal submucosa covered expandable Z stents for treatment of tracheal injury: an experimental pilot study in swine. J Vasc Interv Radiol 11: 1325-30, 2000.

54.Pavcnik D, Uchida BT, Timmermans H, Corless CL, Loriaux M, Keller FS, and Rosch J. The square stent-based large vessel occluder: an experimental pilot study. J Vasc Interv Radiol 11: 1227-34, 2000.

55.Rabkin JM, Orloff SL, Corless CL, Benner KG, Flora KD, Rosen HR, and Olyaei AJ. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg. 179: 426-430, 2000.

56.Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, Orloff, SL, and Rosen HR. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 7:181-190, 2001.

57.Rabkin, JM, Corless CL, Rosen HR, and Olyaei, AJ. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. Transplant Proc 33:1532-1534, 2001.

58.Rabkin JM, Rosen HR, Corless CL, Orloff SL, and Olyaei AJ. Prophylactic antiviral therapy in CMV high-risk liver transplant recipients. Transplant Proc 33: 1811-1812, 2001.

59.Subramanian S, Bourdette DN, Corless C, Vandenbark AA, Offner H, Jones RE. T lymphocytes promote the development of bone marrow-derived APC in the central nervous system. J Immunol 166: 370-6, 2001.

60.Fennerty MB, Corless CL, Sheppard B, Sampliner RES, Faigel DO, Lieberman DA, Weinstein W. Pathologic documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy. Gut 49:142-4, 2001.

61.Yamada K, Pavcnik D, Uchida BT, Timmermans HA, Corless CL, Yamakado K, Park JW, Rosch J, Keller FS, Satou M, Yamada R.Endoluminal treatment of ruptured abdominal aortic aneurysm with small intestinal submucosa sandwich stent-grafts: an experimental study in sheep. Cardiovasc Intervent Radiol 24:99-105, 2001.

62.Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei A.J. Late mortality after orthotopic liver transplantation. Am J Surg 181:475-9, 2001.

63.Faigel DO, Gopal D, Weeks DA, Corless C.Cap-assisted endoscopic submucosal resection of a pancreatic rest. Gastrointest Endoscopy 54:782-4, 2001.

64.Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT positive malignancies. J. Clin. Oncology 20:1692-1703, 2002.

65.Pavcnik D, Uchida BT, Timmermans HA, Corless CL, O'Hara M, Toyota N, Moneta GL, Keller SK, Rosch J. Percutaneous bioprosthetic venous valve: A long-term study in sheep. J Vasc Surg 35:598-602, 2002.

66.Orloff SL, Streblow DN, Soderberg-Naucler C, Yin Q, Kreklywich C, Corless CL, Smith PA, Loomis C, Mills L, Cook JW, de La Melena T, Bruggeman CA, Nelson JA, Wagner CR.Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 73:679-688, 2002.

67.Corless CL, McGreevey L,HaleyA, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002.

68.Petty JK, He K, Corless CL, Vetto JT, Weinberg AD. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 183:512-8, 2002.

69.Rabkin J.M., Corless C.L., Rosen H.R., Olyaei A.J. Immunosuppression impact on long-term cardiovascular complications after liver transplantation.Am J Surg 183:595-9, 2002.

70.Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 33:459-465, 2002[NOTE: This paper was also published in Int J Pathology 10:81-89, 2002]

71.Bagby SP, LeBard LS, Luo Z, Speth RC, Ogden BE, Corless CL. Angiotensin II Type 1 and 2 receptors in conduit arteries of normal developing microswine. Arterioscler Thromb Vasc Biol 22:1113-1121, 2002.

72.Rabkin JM, Rosen HR, Corless CL, Olyaei AJ. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. Transplant Proc 34:1557-1558, 2002.

73.Demetri GD, von Mehren M, Blanke CD, Van den Abbeele A, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman S, Silberman S, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Eng J Med 372:472-480, 2002.

74.Hunt GC, Corless CL, Terry AB, Katon RM. Embryonal rhabdomyosarcoma in a 3-year-old child diagnosed at ERCP: Case report and review. Gastrointest Endosc 56:445-7, 2002.

75.Karamlou T, Vetto JT, Corless C, DeLoughery T, Faigel D, Blanke C. Metastatic breast cancer manifested as refractory anemia and gastric polyps. South Med J 95:922-925, 2002.

76.Bagby SP, LeBard LS, Luo Z, BE, Corless CL, McPherson ED, Speth RC. AngII AT1 and AT2 receptors in developing kidney of normal microswine. Am J Physiol Renal Physiol 283:F755-64, 2002.

77.Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri G, Fletcher CDM, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003.

78.Streblow DN, Kreklywich C, Yin Q, De La Melena VT, Corless CL, Smith PA, Brakebill C, Cook JW, Vink C, Bruggeman C, Nelson JA, Orloff SL. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virology 77:2182-2194, 2003.

79.Brountzos E, Pavcnik D, Timmermans HA, Corless C, Uchida BT, Nihsen ES, Nakata M, Schoder M, Kaufman JA, Keller FS, Rosch J. Remodeling of suspended small intestinal submucosa venous valve: an experimental study in sheep to assess the host cells' origin. J Vasc Interv Radiol 14:349-356, 2003.

80.Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S, Schütte J. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 51:261-265, 2003.

81.Jazrawi SF, Zaman A, Muhammad Z, Rabkin JM, Corless CL, Olyaei A, Biggs A, Ham J, Chou S, Rosen HR. Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection following liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transplantation 9:377-382, 2003.

82.Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, Einhorn L. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ cell tumors. Annals of Oncology 14:873-80, 2003

83.López-Bermejo A, Khosravi J, CorlessCL, Krishna RG, DiamandiA, BodaniU, MistryJ, Kofoed EM, GrahamDL, HwaV, RosenfeldRG. Generation of anti-insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/MAC25) monoclonal antibodies and immunoassay: quantification of IGFBP-rP1 in human serum and distribution in human fluids and tissues. J Endocrinol & Metab 88:3401-3408, 2003.

84.Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J Clin Gastroenterol 37:344-7, 2003.

85.Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 138: 852-858, 2003.

86.Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL. Absence of BRAF And NRAS mutations in uveal melanoma. Cancer Research 63:5761-5766, 2003.

87.Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen C-J, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA.Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J Clin Onc 21:4342-4349, 2003.

88.Pavcnik D, Andrews RT, Yin Q, Uchida BT, Timmermans HA, Corless C, Toyota N, Nakata M, Kaufman J, Keller FS, Rosch J. A canine model for studying endoleak after endovascular aneurysm repair. J Vasc Interv Radiol. 14:1303-10, 2003.

89.Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene 22:8852-60, 2003.

90.Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC. Characterization of KIT mutations in seminomas and sensitivity to imatinib mesylate (formerly STI571). Am J Pathol 164:305-313, 2004.

91.Schoder M, Pavcnik D, Uchida BT, Corless C, Timmermans HA, Yin Q, Brountzos E, Nakata M, Hiraki T, Niyyati M, Kaufman JA, Keller FS, Rosch J. Small intestinal submucosa aneurysm sac embolization for endoleak prevention after abdominal aortic aneurysm endografting: a pilot study in sheep. J Vasc Interv Radiol. 15:69-83, 2004.

92.McPherson EA, Luo Z, Brown RA, LeBard LS, Corless CL, Speth RC, Bagby SP. Chymase-like AngII-generating activity in end-stage human autosomal dominant polycystic kidney disease. Am J Nephrol 15:493-500, 2004.

93.West RB, Corless CL, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball C, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M. The novel marker DOG1 is ubiquitously expressed in GI stromal tumors irrespective of KIT and PDGFRA mutation status. Am J Pathol 165:107-113, 2004.

94.*Medeiros F, *Corless CL, Duensing A, Hornick JL, Oliviera AM, Heinrich MC, Fletcher JA, Fletcher CDM. KIT-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. Am J Surg Pathol 28:889-894, 2004. *Co-first authors.

95.Lu S-L, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ. Overexpression of TGF?1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Research 64:4405-4410, 2004.

96.Kaimaktchiev V, Terracciano L, Tornillo L, SpichtinH, StoiosD, BundiM, KorchevaV, MirlacherM, LodaM, Sauter G, Corless CL. Selective staining of gastrointestinal adenocarcinomas by the homeobox intestinal differentiation factor CDX2. Modern Pathology 17:1392-1399, 2004.

97.Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, Corless CL, Demetri GD, Fletcher CDM, Fletcher JA. Protein Kinase C theta (PKC?) expression and constitutive activation in gastrointestinal stromal tumors (GIST). Cancer Research 64:5127-5131, 2004.

98.Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004.

99.SubramanianS, West RB, CorlessCL, RubinBP, ChuK-M, LeungSY, YuenST, Zhu S, Hernandez-BoussardT, MontgomeryK, NielsenTO, PatelR,GoldblumJR, HeinrichMC, FletcherJA,van de RijnM. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23:7780-90, 2004.

100.Corless CL, McGreevey L, Town A, Schroeder A, Bainbridge T, Harrell P, Fletcher JA, Heinrich MC. KIT Gene deletions at the intron 10 – exon 11 boundary. J Molecular Diagnostics 6:366-370, 2004.

101.Beer TM,Myrthue A,Garzotto M,O'Hara MF,Chin R,Lowe BA, Montalto MA,Corless CL,Henner WD. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiology, Biomarkers & Prevention 13:2225-2232, 2004.

102.Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, Fleming WH. Transplanted human bone marrow contributes to vascular endothelium. Proc Nat'l Acad Sci 101:16891-6, 2004.

103.Weston SJ,Leistikow RL, Reddy KRR,Torres M,Wertheimer AM,Lewinsohn DM,Chou S,Davey MP, Corless C, O'Farrelly C, Nelson DR, Rosen HR. Reconstitution of hepatitis C virus-specific T-cell–mediated immunity after liver transplantation. Hepatology 41:72-81, 2005.

104.Korcheva V, Wong J, Corless C, Iordanov M, Magun B. Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome. Am J Pathol 66:323-39, 2005.

105.McArthur GA, Demetri GD, Van Oosterom A, Heinrich MC, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib. J Clin Onc 23:866-873, 2005.

106.Schneider-Stock R, Boltze C, LasotaJ,Peters B, CorlessC, RuemmeleP, TerraccianoL, ProssM, InsabatoL, Di VizioD, DirnhoferS, HartmannA, Miettinen M, RoessnerA, Tornillo L. Loss of P16 protein defines high-risk patients with GISTs – A tissue microarray study. Clinical Cancer Res 11:638-645, 2005.

107.WestRB, NuytenDSA, SubramanianS, NielsenTO, CorlessCL, RubinBP, MontgomeryK, ZhuS, PatelR, Hernandez-BoussardT, GoldblumJR, BrownPO, van de VijverM, van de RijnM. Determination of Stromal Signatures in Breast Carcinoma. PLoS Biol. 3(6):e187, 2005.

108.Devi DR, Beer TM, Corless CL, Arora V, Weller D, Iversen PL. In vivo Bioavailability and Pharmacokinetics of a c-myc Antisense Phosphorodiamidate Morpholino Oligomer, AVI4126, in Solid Tumors. Clinical Cancer Res 11:3930-8, 2005.

109.CorlessCL, SchroederA, GriffithD, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. PDGFRA mutations in gastrointestinal stromal tumors:Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Onc 23:5357-64, 2005.

110.Han G, Lu S-H, Li AG, He W, Corless CL, Kulesz-MartinM, Wang X-J. Distinct mechanisms of TGF1-mediated epithelial-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Inves. 115:1714-23, 2005.

111.SubramanianS, WestRB, MarinelliRJ, NielsenTO,RubinBP, GoldblumJR, 206:433-44, 2005.

112.Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Comm 332:800-7, 2005.

113.Seong CK, Pavcnik D, Uchida BT, Anai H, Timmermans H, Niyyati M, Corless CL, Correa LO, Keller FS, Rösch J. Experimental percutaneous extrahepatic portacaval shunt creation by transjugular approach in Swine. Cardiovasc Intervent Radiol 28:616-23, 2005.

114.O'Riain C, CorlessCL, HeinrichMC, Keegan D, VioreanuM, MaguireD, Sheahan K. Familial gastrointestinal stromal tumours: an interesting case with unusual genetic and pathological features. Am J Surg Path 29:1680-1683, 2005.

115.West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, Van de Rijn M. A landscape effect in tenosynovial giant cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci 103:690-695, 2006.

116.SenguptaS, ChevilleJC, CorlessCL, LohseCM, HeinrichMC, KwonED, ZinckeH, BluteML, Leibovich BC. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol 175:53-56, 2006.

117.Vartanian V, Lowell B, Minko IG, Wood TG, Ceci JD, George S, Ballinger SW, Corless CL, McCullough AK, Lloyd RS. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci USA103:1864-1869, 2006.

118.Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Onc 29:12-3, 2006.

119.HeinrichMC, McArthur GA, DemetriGD, JoensuuH, BonoP, HerrmanR, HirteH, GianniL, KoslinDB, CorlessCL, DirnhoferS, van Oosterom A, NikolovaZ, DimitrijevicS, FletcherJA, for the Imatinib Target Exploration Consortium (ITEC Study B2225). Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Onc 24:1195-1202, 2006.

120.Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulieres D, Swallow CJ, Verma S. Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Can J Gastroenterol.20:157-63, 2006.

121.Anai H, Uchida BT, Pavcnik D, Seong CK, Baker P, Correa LO, Corless CL, Geyik S, Yavuz K, Sakaguchi H, Kichikawa K, Keller FS, Rosch J. Effects of Blood Flow and/or Ventilation Restriction on Radiofrequency Coagulation Size in the Lung: An Experimental Study in Swine. Cardiovasc Intervent Radiol. 29:838-45, 2006.

122.Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-KellyE, Rubin BP. Extragastrointestinal stromal tumors (EGISTs) presenting as vulvovaginal/rectovaginal septal masses:a diagnostic pitfall. Int J Gynecol Pathol. 25:288-292, 2006.

123.Netto GJ, Watkins DL, Williams JW, Colby TV, dePetris G, Sharkey FE, Corless CL, Lewin D, Petrovic L, Sharma S, Kanel G, Theise N, West AB, Koehler A, Jhala NC, Lefkowitch J, Lezzoni J, Jennings LW, Tillery GW, Klintmalm GB; The Hepatitis C 3 Trial Group. Interobserver agreement in hepatitis C grading and staging and Banff grading schema for acute cellular rejection: The "Hepatitis 3" multi-institutional trial experience. Archives Path Lab Med 130:1157-62, 2006.

124.Yavuz K, Geyik S, Pavcnik D, Uchida BT, Corless CL, Hartley DE, Goktay A, Correa LO, Timmermans H, Hodde JP, Kaufman JA, Keller FS, Rosch J. Comparison of the endothelialization of small intestinal submucosa, dacron, and expanded polytetrafluoroethylene suspended in the thoracoabdominal aorta in sheep. J Vasc Interv Radiol. 17:873-82, 2006.

125.Lu S-L, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang C-F, Siddiqui Y, Nord J, Andersen P, Corless CL, Wang X-J. Loss of transforming growth factor-ß type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes & Development 20:1331-42, 2006.

126.Gupta M, Sheppard BC, Corless CL, MacDonell KR, Blanke CD, Billingsley KG. Outcome following aggressive surgical therapy for gastrointestinal stromal tumors. J Gastrointest Surg 10:1099-1105, 2006.

127.Heinrich MC, Corless CL, Blanke CD, Demetri, GD, Joensuu H, Roberts PJ, Eisenberg B, von Mehren M, Fletcher CDM, Sandau K, McDougall K, Ou WB, Chen C-J, Fletcher JA.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Onc 24:4764-74, 2006.

128.Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K, White C Jr, Granter S, Heinrich MC. Allele-Specific Polymerase Chain Reaction for the Imatinib-Resistant KIT D816V and D816F Mutations in Mastocytosis and Acute Myelogenous Leukemia.J Mol Diagn 8:604-12, 2006.

129.Coffey RJ, Washington MK, Corless CL, Heinrich MC. Menetrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Inves 117:70-80, 2007.

130.Stewart DR, Corless CL, Rubin BP, Heinrich MC, Messiaen LM, Kessler LJ, Zhang PJ, Brooks DG. Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumors (GISTs) in neurofibromatosis type 1. J Med Genetics 44(1):e61, 2007.

131.Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO.TLE as a diagnostic marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Path 31:240-246, 2007.

132.Emery RE, Stevens JS, Nance RW, Corless CL, Vetto JT. Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomes. Am J Surgery 193:618-622, 2007.

133.Agaimy A, Pelz AF, Corless CL, Wunsch PH, Heinrich MC, Hofstaedter F, Dietmaier W, Blanke CD, Wieacker P, Roessner A, Hartmann A, Schneider-Stock R. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: A report of three new cases with mutational analysis and comparative genomic hybridization. Oncol Rep 18:9-15, 2007.

134.Le D, Marks D, Lyle E, Corless CL, Diggs BS, Jobe BA, Kay T, Deveney CW, Wolfe BM, Roberts CT Jr, O'Rourke RW. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc 21:1593-9, 2007.

135.Gareau D, Merlino G, Corless C, Kulesz-Martin M, Jacques S.Noninvasive imaging of melanoma with reflectance mode confocal scanning laser microscopy in a murine model. J Inves Dermatol 127:2184-90, 2007.

136.Demetri GD, Benjamin RS, Blanke CD, Blay J-Y, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CDM, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PWT, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J. NCCN Task Force Report: Optimal Management of Patients with Gastrointestinal Stromal Tumor (GIST) – Update of the NCCN Clinical Practice Guidelines. J Natl Comprehensive Cancer Network 5 (supplement 2):S1-S27, 2007.

137.ZamanZ, RosenHR, IngramK, CorlessCL, OhE, Smith K. Prospective assessment of Fibrospect II to detect hepatic fibrosis in patients with chronic hepatitis C. Am J Med 2007 120:280, e9-14, 2007.

138.Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD. Clonal evolution of resistance to imatinib in patients with metastatic GIST: molecular and radiologic evaluation of new lesions. Clin Cancer Res 13:5398-405, 2007.

139.Schmidt JF, Derr V, Heinrich MC, Crum CP, Fletcher JA, Corless CL, Nosé V. BRAF mutations in malignant struma ovarii. Am J Surg Pathol 31:1337-1343, 2007

140.Graham J, Debiec-Rychter M, Corless CL, Reid R, Davidson R, White JD. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. Arch Pathol Lab Med. 131:1393-6, 2007.

141.JanewayKA, LieglB, Harlow A, Le C, Perez-Atayde A, Kozakewich H, CorlessCL, Heinrich MC,FletcherJA. Pediatric KIT and PDGFRA-wildtype gastrointestinal stromal tumors (GISTs) share KIT activation but not genetic mechanisms of progression with adult KIT-mutant GISTs. Cancer Res 67:9084-9088, 2007.

142.Chang EY, Smith CA, Corless CL, Thomas CR Jr., Hunter JG, Jobe BA. Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. Am J Surgery 193:614-7, 2007.

143.Kim MD, Hoppe H, Pavcnik D, Kaufman JA, Uchida BT, Correa LO, Timmermans HA, Park WK, Corless CL, Keller FS, Rosch J. Percutaneous vein occlusion with small intestinal submucosa: An experimental pilot study in swine and sheep. Cardiovasc Intervent Radiol. 30:725-30, 2007.

144.Aubry M-C, Heinrich MC, Molina J, Lewis J, Yang P, Cassivi S, Corless CL. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer 110:2507-10, 2007.

145.Espinosa I, Lee C-H, Kim MK, Rouse B-T, Subramanian S, Montgomery K, Varna S, Corless CL, Heinrich MC, Smith KS, Wang Z, Rubin B, Nielsen TO, Seitz R, Ross D, West RB, Cleary ML, van de Rijn M. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210-218, 2008.

146.Blanke CD, Demetri GD, von Mehren M, Heinrich M, Eisenberg B, Fletcher J, Corless CL, Fletcher CD, Heinz D, Wehre E, Nikolova Z, Joensuu H. Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620-5, 2008.

147.Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M. MicroRNA expression signature of human sarcomas.Oncogene 27:2015-2026, 2008.

148.Lasota J, Corless CL, Michael C. Heinrich MC, Debiec-Rychter M,4RafSciot R, 5EWardelmann E, Merkelbach-Bruse S, Schildhaus H-U, 6Sonja Steigen SE, 7Stachura J, Wozniak A, M.D., 8Cristina Antonescu C, 9Daum O, 10JJavier Martin J, Garcia del Muro J, Miettinen M. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations. A multi-center study on 54 cases. Modern Pathology 21:476-484, 2008.

149.Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE A Major Response to Imatinib Mesylate in KIT Mutated Melanoma. J Clin Onc 26:2046-51, 2008.

150.Sarff M, Edwards D, Dhungel B, Wegmann KW, Corless C, Weinberg AD, Vetto JT. OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas. Am J Surg 195:621-5, 2008.

151.Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; for the Imatinib Target Exploration Consortium Study B2225. Phase II, Open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Can Res 14:2717-2725, 2008.

152.Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, Resnick MB. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 14(20):6440-48, 2008.

153.Wang A, Mattek NC, Corless CL, Lieberman DA, Eisen GM. The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagus. Gastrointest Endosc. 65(5):859-66, 2008.

154.Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 26(33):5360-7, 2008.

155.Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 26(33):5352-9, 2008.

156.Newell AE, Fiedler SE, Ruan JM, Pan J, Wang J, Deininger J, Corless CL, Carr DW. Protein kinase A RII-like (R2D2) proteins exhibit differential localization and AKAP interaction. Cell Motil Cytoskeleton 65(7):539-52, 2008.

157.Liegl B, Kepten I, Le C, Demetri GD, Heinrich MC, Fletcher CDM, Corless CL, Fletcher JA. Substantial heterogeneity of kinase inhibitor resistance mechanisms in GIST. j Pathology 216(1):64-74, 2008.

158.Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT Gene Mutations and Copy Number in Melanoma Subtypes. Clin Cancer Res. 14(21):6821-8, 2008.

159.Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Can Res 14(23):7726-32, 2008.

160.Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal Antibody DOG1.1 Shows Higher Sensitivity Than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes. 33:437-46, 2009.

161.Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V. Leukemia Research 33:735-41, 2009.

162.Robert M, Sofair AN, Thomas A, Bell B, Bialek S, Corless C, Van Ness G, Huie-White S, Stabach N, Zaman A. Comparison of hepatopathologists and community pathologists review of liver biopsies in a population-based cohort of patients with hepatitis C. Clin Gastroenterol & Hepatol 7:335-8, 2009.

163.Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CDM. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: A novel form of tumor progression.Am J Surg Pathol 33(2):218-26, 2009.

164.Schreiner A, Daneshmand S, Bayne A, Countryman G, Corless CL, Troxell ML. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int. J Surg Pathol (epub April 29, 2009).

165.Kampa KM, Acoba JD, Chen D, Gay J, Lee H-J, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan AC,Baily A, Flemming WH, Corless C, Felsher DW, Naumovski L, Lopez CD. Apoptosis stimulating protein of p53 (ASPP2) heterozygous mice are tumor prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A. 106:4390-5, 2009.

166.Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong K-K, Bokemeyer C, Heinrich MC. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther. 8:481-9, 2009.

167.Schreiner A, Daneshmand S, Bayne A, Countryman G, Corless CL, Troxell ML. Distinctive Morphology of Renal Cell Carcinomas in Tuberous Sclerosis. Int J Surg Pathol. 2009 Apr 29. [Epub ahead of print]

168.Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with the multitargeted tyrosine kinase inhibitor sunitinib malate after imatinib failure. Clin. Cancer Res 15(18):5902-9, 2009.

169.Eroglu Y, Lu H, Terry A, Tendler J, Knopes B, Corless C, Byrne WJ, Zhang Z. Pediatric eosinophilic esophagitis: Single-center experience in northwestern USA. Pediatrics International 50:1-5, 2009.

170.Lillis JV, North J, Vetto JT, Corless CL, White KP, Lee KK. Primary scrotal melanoma presenting as a large, amelanotic, exophytic mass. Arch Dermatol 145:1071-2, 2009.

171.Hayman AV, Sofair AN, Manos MM, Thomas A, Terrault N, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A. Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. Medicine 88:302-6, 2009.

172.O'Glasser AY,Scott DL,Corless CL,Zaman A,Sasaki A,Gopal DV,Rayhill SC,Orloff SL,Ham JM,Rabkin JM,Flora K,Davies CH,Broberg CS,Schwartz JM. Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantation. Clin Transplant. 24(5):643–651, 2010.

173.Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nose V. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocrine Pathology 21(2):73-9, 2010.

174.Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat. 120:409-18, 2010.

175.Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 220(1):58-70, 2010.

176.Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol. 23(1):27-37, 2010.

177.Long KB, Butrynski JE, Blank SD, Ebrahim KS, Dressel DM, Heinrich MC, Corless CL, Hornick JL. Primary Extragastrointestinal Stromal Tumor of the pleura: Report of a unique case with genetic confirmation. Am J Surg Pathol. 34(6):907-912, 2010.

178.Ellis MC, Weerasinghe R, Corless CL, Vetto JT. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg. 199:663-8, 2010.

179.Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest. 90(9):1285-94 2010.

180.Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 28(22):3605-10, 2010.

181.Arredondo AR, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, Corless C, Arber DA, Valent P, George TI. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 85(8):600-6, 2010.

182.Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML. Immunohistochemical and Molecular Markers in Breast Phyllodes Tumors. Appl Immunohistochem Mol Morphol. 19(2):119-25, 2011.

183.Kong Y,Si L,Zhu Y,Xu XG,Corless CL,Flaherty K,Li L,Li H,Sheng X,Cui C,Chi Z,Li S,Han M,Mao L,Lu A,Guo J. Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clin Cancer Res.17:1684-91, 2011.

184.Day FL, Desai J, Corless CL, Heinrich MC, Zalcberg J. Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. Med Oncol. 2011 Dec; 28 suppl 1:162-4. PMID: 185.Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. "Pediatric-type" Gastrointestinal Stromal Tumors in Adults: Distinctive Histology Predicts Genotype and Clinical Behavior. Am J Surg Pathol. 35:495-504, 2011. PMID:

186.Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, and Qin S. A phase II, open label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Onc 29(21):2904-9, 2011. PMID: 21690468

187.Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L, Gourley GR. Novel Biomarker Candidates to Predict Hepatic Fibrosis in Hepatitis C Identified by Serum Proteomics. Dig Dis Sci. 56(11):3305-15, 2011. PMID: 188.O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, Cheang EC, Varlamov O, Corless CL, Roberts CT Jr, Marks DL. Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia. 54:1480-90, 2011. PMID: 189.Fuld AD, Speck ME, Harris BT, Simmons NE, Corless CL, Tsongalis GJ, Pastel DA, Hartford AC, Ernstoff MS. Primary Melanoma of the Spinal Cord: A Case Report, Molecular Footprint, and Review of the Literature. J Clin Oncol 29(17):e499-502, 2011. PMID: 21444862

190.BeadlingC, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A,Barney O, Druker BJ, Schuff KG, Corless CL. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Molec Diagn

191.Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova GS, Partin AW, Mori M, Alumkal J. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 6(10):1248-56, 2011. PMID: 21946329

192.Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol.

193.Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, Neuville A, Bouché O, Cervera P, Pretet JL, Tisserand J, Gauthier A, Le Cesne A, Sabourin JC, Scoazec JY, Bonvalot S, Corless CL, Heinrich MC, Blay JY, Aegerter P. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011 Sep 28. [Epub ahead of print] PMID: 21953054

194.Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2011 Oct 12. [Epub ahead of print] PMID: 21994214

195.Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 11(12):865-78, 2011. PMID: 22089421

196.Pantaleo MA, Astolfi A, Nannini M, Ceccarelli C, Formica S, Santini D, Heinrich MC, Corless C, Dei Tos AP, Paterini P, Catena F, Maleddu A, Saponara M, Di Battista M, Biasco G. Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology 59(6):1071-1080, 2011. PMID: 22175887

197.Kelemen K, Kovacsovics T, Braziel R,Corless C, Beadling C, Fan G.RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2011 Dec 7. PMID: 22035377 [Epub ahead of print]

Reviews, Book Chapters, Letters, Editorials And Non-Peer Reviewed Publications

198.MP Bevilacqua, C Corless and SK Lo.Endothelial-leukocyte adhesion molecule-1 (ELAM-1): a vascular selectin that regulates inflammation. In: Cellular and Molecular Mechanisms of Adhesion: Vascular Adhesion Molecules. CG Cochrane and MA Gimbrone, Jr., Editors, Academic Press (1991).

199.PW Kantoff, MB< Garnick, and CL Corless.Cancer of the genito-urinary tract. In: Atlas of Diagnostic Oncology (2nd edition), A. Skarin editor, Mosby-Wolfe, London (1996).

200.Corless CL.Evaluating early stage prostate cancer: What pretreatment criteria best guide therapeutic decision making? Hematology & Oncology Clinics of North America. P.W. Kantoff, editor, W.B. Saunders, Philadelphia (June 1996), pp. 565-579.

201.Renshaw AA and Corless CL.Papillary architecture in renal cell carcinoma. CHECK SAMPLE (AP 96-7), American Society of Clinical Pathologists Press, Chicago (June 1996).

202.Renshaw AA and Corless CL.Prognostic factors in the pathology of prostatic carcinoma. In: Prostate Cancer: A Multidisciplinary Guide. P.W. Kantoff, K.I. Wishnow, and K.R. Loughlin, editors. Blackwell Scientific, Malden, MA (1997), pp. 11-40.

203.Corless, CL. Oncogenesis. Compendium for the Portland Bone Symposium, 1997.

204.Collins J, Corless CL, Deveney K.Pouchitis. Clinical Perspectives in Gastroenterology 5:156-161 (May/June) 2002.

205.Fletcher JA, Fletcher CDM, Rubin BP, Ashman LK, Corless CL, Heinrich MC. KIT Gene Mutations in Gastrointestinal Stromal Tumors: More Complex than Previously Recognized? [Letter to the Editor] Am J of Pathol, 161:737-738, 2002.

206.Heinrich MC, Blanke CD, Corless CL, Druker BJ. Small Molecule Inhibitors of Protein Kinases in the Treatment of Human Cancer. Chapter 54, Cancer Medicine, 6th edition. Holland & Frei, editors. Published by American Cancer Society, 2003.

207.Oh WK, Corless CL, Garnick MB, and Kantoff PW.Cancer of the genito-urinary tract. In: Atlas of Diagnostic Oncology (3rd edition), A. Skarin editor, Mosby-Wolfe, London, 2003.

208.Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CDM, Maki RG, Rubin B, Van den Abbeele AD, von Mehren M. Optimal Management of Patients with Gastrointestinal Stromal Tumors (GIST): Expansion and Update of NCCN Clinical Practice Guidelines. JNCCN 2 (Suppl 1), May 2004.

209.Heinrich MC, Corless CL. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. Cancer Treat Res 120:129-50, 2004.

210.Corless CL. Assessing The Prognosis Of GI Stromal Tumors: A Growing Role For Molecular Testing. Am J Clin Pathol 122:11-13, 2004.

211.Blanke CD, Corless CL. State of the art therapy for GISTs. Cancer Investigation 23:270-276, 2005.

212.Heinrich MC, Corless CL. Gastric GI Stromal Tumors (GISTs): The Role of Surgery in the Era of Targeted Therapy. J Surg Oncol (Seminars) 90:195-207, 2005.

213.Heinrich MC, Corless CL. Does tumor mutational status correlate with clinical response to imatinib? Practice Point in Nature Clinical Practice Oncology 3:600-601, 2006.

214.Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 369(9574):1731-4, 2007.

215.Corless CL, Heinrich MC. Molecular Pathobiology of Gastrointestinal Stromal Sarcomas. Annu Rev Pathol Mech of Dis., vol 3, pp557-586, 2008.

216.Emile JF, Stock N, Corless CL, Sciot R, Schildhaus HU, Brahimi S, Debiec-Rychter M, Wardelmann E, Coindre JM, Blay JY. Dot-like or Golgi-like KIT and PDGFRA staining in GISTs. Am J Surg Pathol 33(1):157-8, 2008.

217.Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Clin Cancer Res 15(24):7510-7518, 2009.

218.Heinrich MC and Corless CL. Oncogenes in context. Nature 467(7317):796-797, 2010.

219.Corless CL. Personalized cancer diagnostics. Science